Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
- DOI
- 10.1111/j.1365-2141.2010.08340.x
- Published
- 2010 Nov
- Container
- British journal of haematology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/j.1365-2141.2010.08340.x,
title = {Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.},
author = {Agathocleous A and Rohatiner A and Rule S and Hunter H and Kerr JP and Neeson SM and Matthews J and Strauss S and Montoto S and Johnson P and Radford J and Lister A},
year = {2010},
journal = {British journal of haematology},
doi = {10.1111/j.1365-2141.2010.08340.x},
url = {https://doi.org/10.1111/j.1365-2141.2010.08340.x}
}RIS
TY - JOUR TI - Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. AU - Agathocleous A AU - Rohatiner A AU - Rule S AU - Hunter H AU - Kerr JP AU - Neeson SM AU - Matthews J AU - Strauss S AU - Montoto S AU - Johnson P AU - Radford J AU - Lister A PY - 2010 JO - British journal of haematology DO - 10.1111/j.1365-2141.2010.08340.x UR - https://doi.org/10.1111/j.1365-2141.2010.08340.x ER -
APA
A, A., A, R., S, R., H, H., JP, K., SM, N., J, M., S, S., S, M., P, J., J, R., & A, L. (2010). Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.. British journal of haematology. https://doi.org/10.1111/j.1365-2141.2010.08340.x
Source records
- pubmed · retrieved 2026-09-27T14:04:57.467Z
- europe-pmc · retrieved 2026-09-27T14:04:57.488Z
- hal · retrieved 2026-09-27T14:04:57.514Z